APA (7th ed.) Citation

Lin, J., Zhang, Y., Zhou, H., Wang, X., & Wang, W. (2015). CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy. Clinical laboratory (Heidelberg), 61(9), 1317. https://doi.org/10.7754/Clin.Lab.2015.150123

Chicago Style (17th ed.) Citation

Lin, Jiayao, Yu Zhang, Houguang Zhou, Xinqing Wang, and Wenwen Wang. "CYP2C9 Genetic Polymorphism Is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy." Clinical Laboratory (Heidelberg) 61, no. 9 (2015): 1317. https://doi.org/10.7754/Clin.Lab.2015.150123.

MLA (9th ed.) Citation

Lin, Jiayao, et al. "CYP2C9 Genetic Polymorphism Is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy." Clinical Laboratory (Heidelberg), vol. 61, no. 9, 2015, p. 1317, https://doi.org/10.7754/Clin.Lab.2015.150123.